FI973118A0 - Lymfotoksiini-alfa/beta-komplekseja ja antilymfotoksiini-beta-reseptorivasta-aineita kasvaimenvastaisina aineina - Google Patents

Lymfotoksiini-alfa/beta-komplekseja ja antilymfotoksiini-beta-reseptorivasta-aineita kasvaimenvastaisina aineina

Info

Publication number
FI973118A0
FI973118A0 FI973118A FI973118A FI973118A0 FI 973118 A0 FI973118 A0 FI 973118A0 FI 973118 A FI973118 A FI 973118A FI 973118 A FI973118 A FI 973118A FI 973118 A0 FI973118 A0 FI 973118A0
Authority
FI
Finland
Prior art keywords
beta
activating agent
lhc
carrier
lymphotoxin
Prior art date
Application number
FI973118A
Other languages
English (en)
Swedish (sv)
Other versions
FI119359B (fi
FI973118A (fi
Inventor
Jeffrey L Browning
Werner Meier
Christopher D Benjamin
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of FI973118A0 publication Critical patent/FI973118A0/fi
Publication of FI973118A publication Critical patent/FI973118A/fi
Application granted granted Critical
Publication of FI119359B publication Critical patent/FI119359B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
FI973118A 1995-01-26 1997-07-25 Lymfotoksiini-alfa/beta-komplekseja ja anti-lymfotoksiini-beta-reseptor ivasta-aineita kasvaintenvastaisina aineina FI119359B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37896895A 1995-01-26 1995-01-26
US37896895 1995-01-26
US9601386 1996-01-26
PCT/US1996/001386 WO1996022788A1 (en) 1995-01-26 1996-01-26 LYMPHOTOXIN-α/β COMPLEXES AND ANTI-LYMPHOTOXIN-BETA RECEPTOR ANTIBODIES AS ANTI-TUMOR AGENTS

Publications (3)

Publication Number Publication Date
FI973118A0 true FI973118A0 (fi) 1997-07-25
FI973118A FI973118A (fi) 1997-09-25
FI119359B FI119359B (fi) 2008-10-31

Family

ID=23495285

Family Applications (1)

Application Number Title Priority Date Filing Date
FI973118A FI119359B (fi) 1995-01-26 1997-07-25 Lymfotoksiini-alfa/beta-komplekseja ja anti-lymfotoksiini-beta-reseptor ivasta-aineita kasvaintenvastaisina aineina

Country Status (25)

Country Link
EP (2) EP1407781A1 (fi)
JP (2) JPH10513161A (fi)
KR (2) KR100470739B1 (fi)
CN (3) CN1589902A (fi)
AT (1) ATE268604T1 (fi)
AU (1) AU725351B2 (fi)
BG (1) BG62599B1 (fi)
BR (1) BR9606808A (fi)
CA (1) CA2211443A1 (fi)
CZ (1) CZ298711B6 (fi)
DE (1) DE69632681T2 (fi)
DK (1) DK0809510T3 (fi)
EA (1) EA000096B1 (fi)
EE (1) EE04453B1 (fi)
ES (1) ES2220972T3 (fi)
FI (1) FI119359B (fi)
HK (1) HK1006356A1 (fi)
HU (1) HUP9801746A3 (fi)
NO (1) NO322744B1 (fi)
NZ (1) NZ303405A (fi)
PL (1) PL185364B1 (fi)
PT (1) PT809510E (fi)
RO (1) RO118634B1 (fi)
SK (1) SK286497B6 (fi)
WO (1) WO1996022788A1 (fi)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7118742B2 (en) * 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6140467A (en) * 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
DE69931944T2 (de) 1998-10-09 2007-02-08 Biogen Idec Ma Inc., Cambridge Umkehr des viral-induzierten systemischen schocks und des atemnotsyndroms durch blockierung des lymphotoxin-beta- aktivierungsweges
EP1326897A2 (en) * 2000-10-13 2003-07-16 Biogen, Inc. Humanized anti-lt-beta-r antibodies
AU2003248782A1 (en) * 2002-07-01 2004-01-19 Biogen Idec Ma Inc. Humanized anti-lymphotoxin beta receptor antibodies
PL377611A1 (pl) * 2002-12-20 2006-02-06 Biogen Idec Ma Inc. Czynniki dla receptora limfotoksyny beta w połączeniu z czynnikami chemioterapeutycznymi
EP1583503A4 (en) * 2002-12-20 2006-08-09 Biogen Idec Inc POLYVALENT LYMPHOTOXIN BETA RECEPTOR AGONISTS AND THERAPEUTIC USE THEREOF
JP5091476B2 (ja) 2003-06-27 2012-12-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド 均質な抗体溶液の生成のための疎水性相互作用クロマトグラフィーまたはヒンジ領域改変の使用
WO2005092927A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
EP1764371A1 (de) * 2005-04-25 2007-03-21 Xantos Biomedicine AG Agonistische Antikörper, welche an den LT-Beta-Rezeptor binden und dadurch Adipositas assoziierte Phänotypen modulieren, und deren Verwendung in der Therapie
CN101073665B (zh) * 2006-05-17 2014-11-26 上海复旦张江生物医药股份有限公司 淋巴毒素在制备增加化疗药物敏感性的药物中的应用
WO2008042436A2 (en) 2006-10-03 2008-04-10 Biogen Idec Ma Inc. Biomarkers and assays for the treatment of cancer
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
US8067375B2 (en) 2006-10-20 2011-11-29 Biogen Idec Ma Inc. Treatment of demyelinating disorders with soluble lymphotoxin-β-receptor
BRPI0913687A2 (pt) * 2008-09-30 2015-10-13 Genentech Inc marcadores biológicos preditivos da resposta da artrite reumatóide aos antagonistas da linfotoxina
IN2014CN04961A (fi) * 2011-12-05 2015-09-18 Igenica Biotherapeutics Inc
IL308212A (en) 2015-01-20 2024-01-01 Igm Biosciences Inc Tumor necrosis factor-α receptor binding molecules and their uses
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6124599A (ja) * 1984-07-11 1986-02-03 Kyowa Hakko Kogyo Co Ltd 新規ヒトインタ−フエロン−ｒポリペプチド誘導体
JPS61277628A (ja) * 1985-06-04 1986-12-08 Asahi Chem Ind Co Ltd 癌治療用白血球刺激材
US4770995A (en) * 1985-08-29 1988-09-13 New York Blood Center, Inc Detection of the sensitivity of cells to the effects of tumor necrosis factor and lymphotoxin
AU8228891A (en) * 1990-06-27 1992-01-23 Biogen, Inc. Surface complexed lymphotoxin
EP0672143B1 (en) * 1992-12-04 2008-06-04 Biogen Idec MA Inc. Lymphotoxin-beta, lymphotoxin-beta complexes, pharmaceutical preparations and therapeutic uses thereof

Also Published As

Publication number Publication date
CZ236197A3 (cs) 1998-02-18
DE69632681D1 (de) 2004-07-15
FI119359B (fi) 2008-10-31
CA2211443A1 (en) 1996-08-01
WO1996022788A1 (en) 1996-08-01
KR19980701816A (ko) 1998-06-25
SK98697A3 (en) 2000-02-14
CZ298711B6 (cs) 2008-01-02
AU725351B2 (en) 2000-10-12
EP1407781A1 (en) 2004-04-14
KR100470739B1 (ko) 2005-09-02
HK1006356A1 (en) 1999-02-26
PT809510E (pt) 2004-09-30
DE69632681T2 (de) 2005-06-09
CN1900116A (zh) 2007-01-24
CN1589902A (zh) 2005-03-09
MX9705629A (es) 1997-10-31
BG62599B1 (bg) 2000-03-31
EA000096B1 (ru) 1998-08-27
KR100475492B1 (ko) 2005-03-14
NO973385L (no) 1997-09-25
PL185364B1 (pl) 2003-04-30
PL321758A1 (en) 1997-12-22
ES2220972T3 (es) 2004-12-16
FI973118A (fi) 1997-09-25
JPH10513161A (ja) 1998-12-15
HUP9801746A2 (hu) 1998-11-30
AU4970496A (en) 1996-08-14
EP0809510B1 (en) 2004-06-09
EA199700144A1 (ru) 1997-12-30
EE9700255A (et) 1998-04-15
SK286497B6 (sk) 2008-11-06
NO973385D0 (no) 1997-07-22
HUP9801746A3 (en) 2000-11-28
BR9606808A (pt) 1997-12-30
CN1177302A (zh) 1998-03-25
EE04453B1 (et) 2005-04-15
JP2007169296A (ja) 2007-07-05
RO118634B1 (ro) 2003-08-29
ATE268604T1 (de) 2004-06-15
NO322744B1 (no) 2006-12-04
CN1146442C (zh) 2004-04-21
NZ303405A (en) 2000-02-28
KR20040102364A (ko) 2004-12-04
BG101855A (en) 1998-04-30
EP0809510A1 (en) 1997-12-03
DK0809510T3 (da) 2004-10-04

Similar Documents

Publication Publication Date Title
FI973118A0 (fi) Lymfotoksiini-alfa/beta-komplekseja ja antilymfotoksiini-beta-reseptorivasta-aineita kasvaimenvastaisina aineina
Wang et al. Advancing to the era of cancer immunotherapy
Aragane et al. Involvement of dectin-2 in ultraviolet radiation-induced tolerance
DE69841164D1 (de) Sphingosin-1-phosphat-lyase polypeptide, polynukleotide und modulierende mitteln, und verfahren zu deren verwendung
MX9709324A (es) Compuestos terapeuticos que comprenden anticuerpos anti receptores fc.
YU83600A (sh) Adenozin a3 receptorski modulatori
EP0734264A4 (en) CONNECTIONS SPECIFICALLY BINDING TO COLORECTAL CANCER CELLS AND METHOD FOR THEIR PRODUCTION
AU2332188A (en) Compounds having antiprogestational and anti-estrogenic activities for the treatment of hormone-dependent tumors
IL128003A0 (en) Therapeutic multispecific compounds comprised of anti-fcalpha receptor antibodies
KIRKPATRICK et al. Stereospecific glucocorticoid binding to subcellular fractions of the sensitive and resistant lymphosarcoma P1798
NO20003552D0 (no) Progesteron-agonistforbindelser, farmasøytiske sammensetninger inneholdende disse og anvendelsen av forbindelsen, samt en fremgangsmÕte for bestemmelse av tilstedeværelse av steroidreseptorer, ligand-steroidreseptorkomplekser og en fremgangsmÕte
EP0330201A3 (en) Method of enhancing the effect of cytotoxic agents
UA42806C2 (uk) Система для одночасного трансдермального введення кількох активних начал
AU3376297A (en) Human thyrotropin receptor compositions and use thereof
Byfield et al. Mice, men, mustards and methylated xanthines: the potential role of caffeine and related drugs in the sensitization of human tumours to alkylating agents
GR3025698T3 (en) NOVEL GABAa RECEPTOR SUBTYPES AND METHODS FOR SCREENING DRUG COMPOUNDS USING IMIDAZOQUINOXALINES AND PYRROLOPYRIMIDINES TO BIND TO GABAa RECEPTOR SUBTYPES.
WO1997041225A3 (en) Mammalian mixed lymphocyte receptors, chemokine receptors [mmlr-ccr]
ATE404676T1 (de) Prostat-spezifisches-antigenformen und verfahren zu ihrer bestimmung
WO1995016709A3 (en) Anti-mullerian hormone receptor polypeptides and antibodies thereto
WO2002053195A3 (en) System for, and method of, irradiating article with x-ray beam
DK0943014T3 (da) Fremgangsmåder til diagnosticering af glaukom og opdagelse af antiglaukome lægemidler
Raleigh et al. Reductive activation of nitroaromatics and enzyme inhibition: Misonidazole and xanthine oxidase
Andres et al. Phylogenetic disparity influences the predominance of direct over indirect pathway of antigen presentation in islet xenotransplantation
NO965347L (no) Fremgangsmåte for fremstilling av cytolytiske T-celler som er spesifikke for et peptid/MHC-kompleks
Mehringer Properties of invariant chain relevant to intracellular trafficking patterns and antigen presentation function of class II molecules

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: BIOGEN IDEC MA INC.

Free format text: BIOGEN IDEC MA INC.

FG Patent granted

Ref document number: 119359

Country of ref document: FI